COO COOPER COMPANIES, INC.

CIK 0000711404 44 ready 8-Ks latest June 4, 2026, 4:27 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 44

Latest filing June 4, 2026, 4:27 PM ET

Top materiality 0.90

Event mix earnings ×19 · leadership ×9 · other_material ×5

Sentiment 17 pos · 0 neg · 27 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for COO

Highest-materiality recent filing

CooperCompanies Q2 revenue $1.082B (+8% YoY); non-GAAP EPS $1.21 (+26%); records $271.6M litigation charge

June 4, 2026, 4:27 PM ET other material materiality 0.90 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases ×2

Revenue $1.082B (+8% reported, +5% organic); CooperVision $723.5M (+8%), CooperSurgical $358.0M (+8%).
GAAP diluted EPS of $(0.40) due to $271.6M net litigation charge; non-GAAP diluted EPS $1.21, up 26% YoY.

Read filing →

June 4, 2026, 4:27 PM ET other material materiality 0.90 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases ×2

CooperCompanies Q2 revenue $1.082B (+8% YoY); non-GAAP EPS $1.21 (+26%); records $271.6M litigation charge

Revenue $1.082B (+8% reported, +5% organic); CooperVision $723.5M (+8%), CooperSurgical $358.0M (+8%).
March 5, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

CooperCompanies Q1 revenue $1.024B, non-GAAP EPS $1.10; raises FY2026 guidance

Q1 revenue $1.024B (+6% reported, +3% organic); GAAP EPS $0.66 (+27%), non-GAAP EPS $1.10 (+20%).
December 23, 2025, 6:59 PM ET leadership materiality 0.65 neutral item 1.01 item 5.02 item 7.01 item 9.01 ◈ Material Agreements

CooperCompanies appoints former STERIS CEO Rosebrough to board; agrees with Browning West

Walter M. Rosebrough Jr., former STERIS CEO, appointed as independent director effective Jan 3, 2026; joins Governance & Nominating Committee.
December 4, 2025, 6:59 PM ET earnings materiality 0.90 positive item 2.02 item 5.02 item 7.01 item 9.01

CooperCompanies reports Q4 FY2025 revenue up 5%, appoints new Chairman, launches strategic review

Q4 FY2025 revenue $1,065.2M (+5% reported, +3% organic); GAAP EPS $0.43 (-27%), non-GAAP EPS $1.15 (+11%)
August 27, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

CooperCompanies Reports Q3 2025 Revenue of $1.0603B, Up 6%; Non-GAAP EPS $1.10, Up 15%

Revenue grew 6% to $1,060.3 million; CooperVision up 6% to $718.4M, CooperSurgical up 4% to $341.9M.
May 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

CooperCompanies Q2 revenue $1.00B, up 6% YoY; non-GAAP EPS $0.96 (+14%)

Revenue $1,002.3M (+6% YoY); GAAP EPS $0.44 flat; non-GAAP EPS $0.96 (+14%).
March 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CooperCompanies Q1 revenue $964.7M (+4% YoY); non-GAAP EPS $0.92; raises FY EPS outlook to $3.94-$4.02

Revenue $964.7M (+4% reported, +5% constant currency, +5% organic); GAAP diluted EPS $0.52 (vs $0.41), non-GAAP diluted EPS $0.92 (vs $0.85).
December 5, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

CooperCompanies Q4 revenue $1.02B (+10% YoY), non-GAAP EPS $1.04, up 19%; FY25 guide $4.08-$4.16B

Q4 revenue $1,018.4M (+10% YoY), GAAP EPS $0.58 (+38%), non-GAAP EPS $1.04 (+19%).
August 28, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

CooperCompanies Q3 revenue up 8% to $1,002.8M; raises FY 2024 guidance

Revenue $1,002.8M (+8% YoY); GAAP diluted EPS $0.52 (+22%), non-GAAP diluted EPS $0.96 (+14%).
May 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CooperCompanies Q2 revenue $942.6M (+7% YoY), raises FY2024 guidance

GAAP diluted EPS $0.44 (up 122% YoY); non-GAAP diluted EPS $0.85 (up 10% YoY).
February 29, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Cooper Q1 revenue record $931.6M (+9% YoY); non-GAAP EPS $0.85 (+18%); FY24 guidance raised

Revenue of $931.6M, up 9% YoY; CooperVision $621.5M (+7%), CooperSurgical $310.1M (+12%).
December 7, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases ×3

Cooper Q4 revenue $927M (+9%); FY2024 guidance $3.81-3.88B; 4-for-1 stock split

Q4 GAAP diluted EPS $1.70 (+29%); non-GAAP diluted EPS $3.47 (+26%). FY GAAP EPS $5.91 (-24%), non-GAAP $12.81 (+3%).
August 30, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

CooperCompanies Q3 revenue $930.2M (+10% YoY); non-GAAP EPS $3.35 (+5%); guides FY23 revenue $3.578-3.595B

Revenue $930.2M up 10% YoY; record quarterly revenue for both CooperVision and CooperSurgical.
June 1, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Cooper Q2 revenue up 6% to $877M; GAAP EPS slumps 69% to $0.80; FY23 guidance updated

Revenue $877.4M, up 6% YoY (9% constant currency, 8% organic); GAAP diluted EPS $0.80 vs $2.55 last year.
March 2, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

CooperCompanies Q1 revenue up 9% to $858.5M; guides FY23 non-GAAP EPS $12.60-$12.90

Revenue $858.5M, up 9% YoY (16% constant currency, 10% organic).
December 8, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases ×3

CooperCompanies Q4 revenue up 12% to $848M, but GAAP EPS falls 40%; FY2023 guidance issued

Q4 GAAP diluted EPS of $1.32 (down 40% YoY); non-GAAP diluted EPS of $2.75 (down 16%).
August 31, 2022, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Cooper Q3 revenue $843.4M (+10% YoY); non-GAAP EPS $3.19 down 6%; FY22 guide $3.29-3.31B

Revenue $843.4M (+10% YoY); CooperVision +2% to $566.3M, CooperSurgical +35% to $277.1M.
June 2, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

CooperCompanies Q2 rev up 15% to $829.8M; GAAP EPS $2.55, adj EPS $3.24

CooperVision revenue $553.8M (+6% reported, +12% organic); toric and multifocal sales strong.
March 3, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

CooperCompanies Q1 revenue up 16% to $787M; non-GAAP EPS $3.24

Revenue $787.2M (+16% YoY); CooperVision +11% to $561.5M, CooperSurgical +30% to $225.7M.
February 7, 2022, 6:59 PM ET M&A materiality 0.80 positive item 1.01 item 7.01 item 9.01

CooperCompanies to acquire Cook Medical's Reproductive Health business for $875M

Deal consideration: $675M at closing plus $200M in four $50M annual installments.
December 17, 2021, 6:59 PM ET M&A materiality 0.85 neutral item 1.01 item 2.01 item 2.03 item 7.01 item 9.01

CooperCompanies completes $1.6B acquisition of Generate Life Sciences, funded by $1.5B term loan

Cooper completed acquisition of Generate Life Sciences for ~$1.605B in cash.
December 2, 2021, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

CooperCompanies reports record FY2021 revenue; Q4 revenue up 11% to $759.1M

Q4 revenue $759.1M (+11% YoY); GAAP EPS $2.21 (+35%); Non-GAAP EPS $3.28 (+4%)
November 10, 2021, 6:59 PM ET M&A materiality 0.75 positive item 1.01 item 7.01 item 9.01

CooperCompanies to acquire Generate Life Sciences for $1.6B cash, expected to close Q1 2022

CooperSurgical unit will acquire Generate, a provider of donor egg/sperm, fertility cryopreservation, and newborn stem cell storage.
September 2, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Cooper Q3 revenue up 32% to $763.4M; non-GAAP EPS $3.41, up 50%; raises FY guidance

Revenue $763.4M (+32% YoY); CooperVision $557.5M (+24%), CooperSurgical $205.9M (+60%).

Executive changes

Appointed

Paul Keel

Director

COO · COOPER COMPANIES, INC.

Effective: 2026-07-01
Filed: May 4, 2026, 7:59 PM ET

approved the appointment of Paul Keel to fill the new director position, effective as of July 1, 2026

Appointed

Barbara Carbone

Director

COO · COOPER COMPANIES, INC.

Effective: 2025-05-01
Filed: April 30, 2025, 7:59 PM ET

to appoint Barbara Carbone to fill the new director position, with effect from May 1, 2025

Departed

William A. Kozy

Director

COO · COOPER COMPANIES, INC.

Filed: February 5, 2025, 6:59 PM ET

On January 31, 2025, William A. Kozy informed the Board of Directors (the "Board") that he will retire as a director, effective on the date of The Cooper Companies, Inc.'s (the "Company's") next Annual Meeting of Stockholders in April 2025 (the "Annual Meeting").

Departed

Gary S. Petersmeyer

director

COO · COOPER COMPANIES, INC.

Filed: December 14, 2023, 6:59 PM ET

On December 12, 2023, Gary S. Petersmeyer informed the Board that he will retire as a director, effective on the date of the Company's next Annual Meeting of Stockholders in March 2024.

Appointed

Lawrence E. Kurzius

Director

COO · COOPER COMPANIES, INC.

Effective: 2023-12-01
Filed: November 30, 2023, 6:59 PM ET

the Board of Directors of the Company (the “Board”) voted to expand the size of the Board from eight directors to nine directors with effect from December 1, 2023 and to appoint Lawrence E. Kurzius to fill the new director position, with effect from December 1, 2023

Departed

Jody S. Lindell

Director

COO · COOPER COMPANIES, INC.

Filed: December 19, 2022, 6:59 PM ET

On December 13, 2022, Jody S. Lindell informed the Board that she will retire as a director, effective on the date of the Company’s next Annual Meeting of Stockholders in March 2023.

Appointed

Cynthia L. Lucchese

Director

COO · COOPER COMPANIES, INC.

Effective: 2022-10-01
Filed: October 4, 2022, 7:59 PM ET

to elect Cynthia L. Lucchese to fill the new director position, with effect from October 1, 2022

Earnings & guidance

2026-Q1 EPS reported $0.66 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

17 positive 0 negative 27 neutral

source · COO on sec.gov